SEC For	m 4																	
FORM 4 UNITED STA				ATE	TES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549											OMB APPROVAL		
Section obligat	this box if no lo n 16. Form 4 or ions may contir tion 1(b).		STATEN	Filed pur	rsuant	to Sectior	า 16(ส	a) of the Seculovestment (urities Exc	change	e Act of 19		SHIP	Estima	Numbe ated av	erage burden	0.5	
1. Name and Address of Reporting Person* Symons Julian A. (Last) (First) (Middle)				- <u>A</u> 3.	2. Issuer Name and Ticker or Trading Symbol <u>Aligos Therapeutics, Inc.</u> [ALGS] 3. Date of Earliest Transaction (Month/Day/Year) 03/01/2024								5. Relationship of Reporting Person(s) to Issuer (Check all applicable) Director 10% Owner X Officer (give title Other (specify below) below) See Remarks				ner	
C/O ALIGOS THERAPEUTICS, INC. ONE CORPORATE DRIVE, 2ND FLOOR (Street) SOUTH SAN CA 94080				4.	4. If Amendment, Date of Original Filed (Month/Day/Year)								Individual or Joint/Group Filing (Check Applicable ne) X Form filed by One Reporting Person Form filed by More than One Reporting Person					
FRANCISCO CAT CATOR (City) (State) (Zip)				_ R	Rule 10b5-1(c) Transaction Indication Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.													
Table I - Non-Deriva 1. Title of Security (Instr. 3) 2. Transa Date (Month/D				ansactio	action 2A. Deemed Execution I			, 3. Transacti Code (Ins	3. Transaction Code (Instr. 5)		of, or Beneficia ities Acquired (A) or d Of (D) (Instr. 3, 4 an		5. Amou	nt of s ally ollowing	Form	Direct of Indirect Estr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)	
								Code V	/ Amo	ount	(A) or (D)	Price	Transact	saction(s) r. 3 and 4)			mətt. 4)	
Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)																		
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transa Code 8)				6. Date Exercisable and Expiration Date (Month/Day/Year)			7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s (Instr. 4)	ly	Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	Beneficial Ownership (Instr. 4)	
				Code	v	(A)	(D)	Date Exercisable	Expirati Date		Title	Amount or Number of Shares						
Stock Option (Right to Buy)	\$1.13	03/01/2024		A		72,000		(1)	03/01/2	034	Common Stock	72,000	\$0	72,000)	D		

Explanation of Responses:

1. 1/48th of the total number of shares vest in forty-eight (48) successive and equal monthly installments measured from March 1, 2024 (the "Vesting Commencement Date"), such that 100% of the shares subject to the option will be fully vested and exercisable on the fourth anniversary of the Vesting Commencement Date, subject to the Reporting Person's continued service through each vesting date. Remarks:

Executive Vice President, Chief Scientific Officer

/s/ Lesley Ann Calhoun, as	
attorney-in fact for Julian A.	03/0
<u>Symons</u>	
** Signature of Reporting Person	Date

03/04/2024

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).

** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.

Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.